UY37517A - Métodos de síntesis de compuestos tiazoles sustituidos - Google Patents

Métodos de síntesis de compuestos tiazoles sustituidos

Info

Publication number
UY37517A
UY37517A UY0001037517A UY37517A UY37517A UY 37517 A UY37517 A UY 37517A UY 0001037517 A UY0001037517 A UY 0001037517A UY 37517 A UY37517 A UY 37517A UY 37517 A UY37517 A UY 37517A
Authority
UY
Uruguay
Prior art keywords
synthesis
substituted
compounds
tiazol
methods
Prior art date
Application number
UY0001037517A
Other languages
English (en)
Inventor
Virginia Tanis
Olaf Kinzel
Gerald Kleymann
Thomas Hoffmannd
Christoph Steeneck
Hariharan Venkatesan
Steven Goldberg
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54754732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY37517(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of UY37517A publication Critical patent/UY37517A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención describe la síntesis de compuestos tiazoles sustituidos; más específicamente la síntesis de 5-(2,3- dicloro-4-(1,1,1,3,3,3-hexafluoro-2-hidroxipropan-2-il)fenil)-N- (2-hidroxi-2-metilpropil)-4-(R1-1-carbonil)tiazol-2-carboxamida y (S)-5-(R2)-N-(2-hidroxi-2-metilpropil)-4-(2-metilpirrolidin -1- carbonil)tiazol-2-carboxamida.
UY0001037517A 2014-10-30 2017-12-14 Métodos de síntesis de compuestos tiazoles sustituidos UY37517A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462072563P 2014-10-30 2014-10-30

Publications (1)

Publication Number Publication Date
UY37517A true UY37517A (es) 2018-01-31

Family

ID=54754732

Family Applications (2)

Application Number Title Priority Date Filing Date
UY0001036377A UY36377A (es) 2014-10-30 2015-10-30 Compuestos tiazoles sustituidos como moduladores del receptor nuclear ror t y composiciones farmacéuticas que los contienen
UY0001037517A UY37517A (es) 2014-10-30 2017-12-14 Métodos de síntesis de compuestos tiazoles sustituidos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UY0001036377A UY36377A (es) 2014-10-30 2015-10-30 Compuestos tiazoles sustituidos como moduladores del receptor nuclear ror t y composiciones farmacéuticas que los contienen

Country Status (40)

Country Link
US (2) US9850236B2 (es)
EP (2) EP3212643B1 (es)
JP (3) JP6998204B2 (es)
KR (2) KR20170127580A (es)
CN (3) CN107108599A (es)
AR (2) AR102480A1 (es)
AU (2) AU2015339087B2 (es)
BR (2) BR122017023050A2 (es)
CA (1) CA2965512C (es)
CL (3) CL2017001042A1 (es)
CO (1) CO2017005014A2 (es)
CR (2) CR20170166A (es)
CY (1) CY1121716T1 (es)
DK (1) DK3212643T3 (es)
EA (2) EA033699B1 (es)
EC (1) ECSP17033054A (es)
ES (2) ES2858503T3 (es)
GT (1) GT201700090A (es)
HK (1) HK1258212A1 (es)
HR (1) HRP20190900T1 (es)
HU (1) HUE043624T2 (es)
IL (2) IL251865A0 (es)
JO (2) JOP20200117A1 (es)
LT (1) LT3212643T (es)
MA (1) MA40873B1 (es)
ME (1) ME03426B (es)
MX (2) MX369567B (es)
PE (2) PE20171649A1 (es)
PH (2) PH12017500800A1 (es)
PL (1) PL3212643T3 (es)
PT (1) PT3212643T (es)
RS (1) RS58613B1 (es)
SG (2) SG11201703323PA (es)
SI (1) SI3212643T1 (es)
SV (1) SV2017005429A (es)
TR (1) TR201907763T4 (es)
TW (2) TWI705057B (es)
UY (2) UY36377A (es)
WO (1) WO2016069974A1 (es)
ZA (3) ZA201703679B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201803869A (zh) * 2016-04-27 2018-02-01 健生藥品公司 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
KR20210060367A (ko) 2018-03-12 2021-05-26 에스칼리에 바이오사이언시스, 비브이 스피로사이클릭 ror-감마 조절제
JP2021517563A (ja) * 2018-03-12 2021-07-26 エスカリア バイオサイエンシーズ，ビーブイ 二環式ＲＯＲγモジュレーター
JP2021527660A (ja) 2018-06-18 2021-10-14 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲγｔのモジュレータとしてのフェニル及びピリジニル置換イミダゾール
WO2019243999A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Phenyl substituted pyrazoles as modulators of roryt
JP2021528398A (ja) 2018-06-18 2021-10-21 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲγＴのモジュレーターとしての６−アミノピリジン−３−イルピラゾール
ES2925473T3 (es) 2018-06-18 2022-10-18 Janssen Pharmaceutica Nv Pirazoles de piridinilo como moduladores de RORyt
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91418A (en) 1988-09-01 1997-11-20 Rhone Poulenc Agrochimie (hetero) cyclic amide derivatives, process for their preparation and fungicidal compositions containing them
CA2195847A1 (en) 1994-07-27 1996-02-08 John J. Talley Substituted thiazoles for the treatment of inflammation
BR0208956A (pt) 2001-04-16 2004-07-13 Tanabe Seiyaku Co Abridor de canais de k ativados por cálcio de grande condutância
MXPA04001400A (es) 2001-08-13 2004-05-27 Janssen Pharmaceutica Nv Derivados de tiazolilo 2,4,5-tri-substituidos y su actividad anti-inflamatoria.
AR045651A1 (es) * 2003-09-19 2005-11-02 Solvay Pharm Bv Derivados de tiazol como moduladores del receptor de cannabinoide
US8188128B2 (en) 2005-05-12 2012-05-29 The University Of Medicine And Dentistry Of New Jersey Opioid receptor subtype-selective agents
GB0518237D0 (en) * 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
AU2007208225B2 (en) 2006-01-25 2013-05-02 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
WO2008064318A2 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Peripheral opioid receptor active compounds
WO2008064317A1 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Lipophilic opioid receptor active compounds
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
EP2586311B1 (de) 2008-07-17 2016-12-14 Bayer CropScience AG Heterocyclische Verbindungen als Schädlingsbekämpfungsmittel
TW201040181A (en) * 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
EP2368886A1 (en) * 2010-03-01 2011-09-28 Phenex Pharmaceuticals AG Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR gamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune desease
US9492439B2 (en) 2010-03-11 2016-11-15 New York University Amido compounds as RORγt modulators and uses thereof
WO2011112264A1 (en) 2010-03-11 2011-09-15 New York University Compounds as rorϒt modulators and uses thereof
WO2011115892A1 (en) 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
WO2012027965A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012074547A2 (en) 2010-11-29 2012-06-07 New York University STEROID COMPOUNDS AS RORγt MODULATORS AND USES THEREOF
WO2012090995A1 (ja) 2010-12-28 2012-07-05 ライオン株式会社 口腔状態の判定方法、並びにそのために用いられる分析用具、装置、及びプログラム
US9012651B2 (en) 2011-03-24 2015-04-21 Abbvie Inc. TRPV3 modulators
US9586928B2 (en) 2011-05-16 2017-03-07 The Scripps Research Institute Modulators of the nuclear hormone receptor ROR
EP2738170B1 (en) 2011-07-29 2017-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
BR112014005268A2 (pt) 2011-09-09 2017-03-28 Univ New York compostos de amido como moduladores de ror t e usos dos mesmos
GB201116641D0 (en) * 2011-09-27 2011-11-09 Glaxo Group Ltd Novel compounds
EP2800745B1 (en) 2011-12-02 2020-02-12 Phenex Pharmaceuticals AG Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rory, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases
US20130190356A1 (en) 2011-12-22 2013-07-25 Genentech, Inc. Benzyl sulfonamide derivatives as rorc modulators
KR101742954B1 (ko) * 2012-05-31 2017-06-02 페넥스 파마슈티컬스 아게 고아 핵 수용체 ror[감마]의 조절제로서의 카복사미드 또는 설폰아미드가 치환된 티아졸 및 관련된 유도체
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
AU2013331505A1 (en) * 2012-10-16 2015-04-30 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ROR-gamma-t
EP2931281B1 (en) * 2012-12-12 2018-01-17 Merck Sharp & Dohme Corp. Amino-pyrimidine-containing spleen tyrosine kinase inhibitors
EP3004081B1 (en) 2013-06-04 2017-11-15 Acturum Real Estate AB Triazole compounds and their use as gamma secretase modulators
CN103333168B (zh) * 2013-07-23 2015-08-05 清华大学 一种酰胺类化合物及其制备方法与应用
CN105705501B (zh) 2013-09-09 2019-04-19 百时美施贵宝公司 RORγ调节剂
US20150072890A1 (en) 2013-09-11 2015-03-12 20/20 Gene Systems, Inc. Methods and compositions for aiding in the detection of lung cancer
WO2015042212A1 (en) 2013-09-20 2015-03-26 Bristol-Myers Squibb Company RORγ MODULATORS
JP6423423B2 (ja) * 2013-10-15 2018-11-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｒｏｒγｔのアルキル結合キノリニルモジュレーター
CN105636952A (zh) * 2013-10-15 2016-06-01 詹森药业有限公司 Rorγt的仲醇喹啉基调节剂
TN2016000224A1 (en) 2013-12-05 2017-10-06 Lead Pharma Holding Bv Ror gamma (rory) modulators
US20160326108A1 (en) 2014-01-06 2016-11-10 Bristol-Myers Squibb Company Pyrrolidinyl sulfone derivatives and their use as ror gamma modulators
WO2015103510A1 (en) 2014-01-06 2015-07-09 Bristol-Myers Squibb Company Heterocyclic sulfone as ror-gamma modulators
JP6548664B2 (ja) 2014-01-06 2019-07-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ シクロヘキシルスルホンＲＯＲγ調節因子
US9771320B2 (en) 2014-01-06 2017-09-26 Bristol-Myers Squibb Company Carbocyclic sulfone RORγ modulators
WO2015145371A1 (en) 2014-03-27 2015-10-01 Piramal Enterprises Limited Ror-gamma modulators and uses thereof
PL3212642T3 (pl) 2014-10-30 2020-04-30 Janssen Pharmaceutica Nv Tiazole podstawione amidami jako modulatory rorgammat
RS58250B1 (sr) 2014-10-30 2019-03-29 Janssen Pharmaceutica Nv Tiazoli kao modulatori roryt

Also Published As

Publication number Publication date
BR122017023050A2 (pt) 2019-09-10
MX367912B (es) 2019-09-11
PT3212643T (pt) 2019-06-17
CN107827841A (zh) 2018-03-23
CR20170542A (es) 2018-02-20
EP3212643B1 (en) 2019-03-20
GT201700090A (es) 2019-08-08
AR110155A2 (es) 2019-02-27
JP2020180129A (ja) 2020-11-05
CN112979630A (zh) 2021-06-18
IL255648B (en) 2020-06-30
JP2019059728A (ja) 2019-04-18
TWI705057B (zh) 2020-09-21
ES2858503T3 (es) 2021-09-30
SG10201805355YA (en) 2018-07-30
TWI667230B (zh) 2019-08-01
CR20170166A (es) 2017-08-22
SI3212643T1 (sl) 2019-04-30
PH12017500800B1 (en) 2017-10-02
TW201629027A (zh) 2016-08-16
UY36377A (es) 2016-04-29
MX369567B (es) 2019-11-12
ES2724556T3 (es) 2019-09-12
ZA201703679B (en) 2019-06-26
TR201907763T4 (tr) 2019-06-21
MX2017005689A (es) 2018-02-19
US20160122336A1 (en) 2016-05-05
CL2017001042A1 (es) 2017-12-01
EA033699B1 (ru) 2019-11-18
KR20170078750A (ko) 2017-07-07
US10150762B2 (en) 2018-12-11
CL2018000436A1 (es) 2018-07-06
PE20171649A1 (es) 2017-11-13
CA2965512A1 (en) 2016-05-06
PE20180250A1 (es) 2018-02-02
CA2965512C (en) 2020-03-10
US9850236B2 (en) 2017-12-26
JO3571B1 (ar) 2020-07-05
EA201790942A1 (ru) 2017-09-29
IL251865A0 (en) 2017-06-29
HRP20190900T1 (hr) 2019-07-12
JOP20200117A1 (ar) 2017-06-16
ZA201805860B (en) 2019-11-27
AR102480A1 (es) 2017-03-01
DK3212643T3 (da) 2019-05-13
HUE043624T2 (hu) 2019-08-28
BR112017008816A2 (pt) 2017-12-19
KR20170127580A (ko) 2017-11-21
WO2016069974A1 (en) 2016-05-06
RS58613B1 (sr) 2019-05-31
ME03426B (me) 2020-01-20
AU2019200228A1 (en) 2019-01-31
AU2019200228B2 (en) 2020-04-16
EP3212643A1 (en) 2017-09-06
MA40873A (fr) 2017-09-05
LT3212643T (lt) 2019-06-10
EA201891562A2 (ru) 2018-12-28
CO2017005014A2 (es) 2017-08-31
MA40873B1 (fr) 2019-07-31
EA201891562A3 (ru) 2019-04-30
JP6998204B2 (ja) 2022-02-04
CL2019001514A1 (es) 2019-10-04
AU2015339087B2 (en) 2020-01-23
CY1121716T1 (el) 2020-07-31
JP6623270B2 (ja) 2019-12-18
US20170327492A1 (en) 2017-11-16
EP3354651B1 (en) 2021-01-06
PH12017502105A1 (en) 2019-11-25
IL255648A (en) 2018-01-31
ECSP17033054A (es) 2018-01-31
CN107108599A (zh) 2017-08-29
SG11201703323PA (en) 2017-05-30
AU2015339087A1 (en) 2017-05-11
ZA201805861B (en) 2019-11-27
HK1258212A1 (zh) 2019-11-08
EA035998B1 (ru) 2020-09-10
EP3354651A1 (en) 2018-08-01
JP2018500287A (ja) 2018-01-11
TW201927759A (zh) 2019-07-16
PH12017500800A1 (en) 2017-10-02
PL3212643T3 (pl) 2019-08-30
SV2017005429A (es) 2017-10-17

Similar Documents

Publication Publication Date Title
UY37517A (es) Métodos de síntesis de compuestos tiazoles sustituidos
IL266214B (en) 5,4,2-tri-converted 4,2,1-triazolones used as dhodh inhibitors
IL248546B (en) A multi-fluorinated compound as an inhibitor of proton tyrosine kinase
EA201790271A1 (ru) Ингибиторы гликозидазы
GEP20186887B (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
MA47420A (fr) Composés inhibiteurs d'oga
HK1258053A1 (zh) 作為蛋白激酶抑制劑的新的2，3，5-取代的噻吩化合物
HK1246297A1 (zh) 3，5-二取代的苯炔基化合物晶體
TN2018000020A1 (en) Colony stimulating factor-1 receptor (csf-1r) inhibitors.
MX2019005333A (es) Sulfonamidas sustituidas para el control de plagas animales.
SG10201805896SA (en) PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS
MA49006A (fr) Inhibiteurs d'ip6k
EA201691999A1 (ru) Новые сульфониламинобензамидные соединения
HUE045851T2 (hu) Eljárás 2-(2,5-dimetil-1H-pirrol-1-il)-1,3-propándiol és helyettesített származékainak elõállítására
PH12017500492A1 (en) Crystalline bace inhibitors
IT201700035964A1 (it) “divisorio per boiserie”
DOP2017000001A (es) Forma polimórfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi)bencilamina para el tratamiento del alzhéimer
UA93524U (uk) 5-(феноксиметил)-4-феніл-4н-1,2,4-триазол-3-тіол, що проявляє жарознижуючу активність
JP1622268S (ja) スライドファスナー
JP1622269S (ja) スライドファスナー
JP1622270S (ja) スライドファスナー
JP1622267S (ja) スライドファスナー
JP1622266S (ja) スライドファスナー
UA97068U (xx) 5-(феноксиметил)-4-етил-1,2,4-триазол-3-тіон, що виявляє гіпоглікемічну активність
IT201700090331A1 (it) "lopemide"